Alkem Laboratories Limited , a prominent player in the Indian pharmaceutical industry, has completed the transfer of its Trade Generics Business to its wholly-owned subsidiary, Alkem Wellness Limited, with a total consideration of ₹532.5 crores.

Business Transfer Completion

On December 30, 2025, the company announced the completion of the business transfer with the final payment of ₹32.5 crores from Alkem Wellness to the parent company. This brings the aggregate sale consideration to ₹532.5 crores under the Business Transfer Agreement.

Timeline of Events

The strategic restructuring process began with the initial intimation to stock exchanges on December 10, 2024. The Business Transfer Agreement was formally executed on September 26, 2025, setting October 1, 2025, as the effective date for the business transfer on a slump sale basis.

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Manish Narang signed the regulatory filing, ensuring transparency for investors and stakeholders.

Strategic Impact

This restructuring move represents a significant step in streamlining Alkem Laboratories' operations. By transferring the Trade Generics Business to Alkem Wellness as a going concern, the company has created a more focused operational structure that could enhance resource allocation and operational efficiency across its business segments.

The completion of this ₹532.5 crore transaction marks a milestone in the company's strategic reorganization efforts, positioning both entities for optimized performance in their respective operational areas.

Alkem Laboratories Limited has disclosed receiving a significant GST demand order from West Bengal tax authorities, totaling ₹9.72 crores for the financial year 2021-22. The pharmaceutical company made this disclosure on December 30, 2025, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GST Order Details

The demand order was issued by the Deputy Commissioner, Large Taxpayer Unit, Corporate Division, West Bengal, and was received by the company on December 29, 2025. The order pertains to the company's West Bengal GSTIN for FY2021-22.

The demand has been raised under the applicable provisions of the Integrated Goods and Services Tax (IGST) Act, 2017, Central Goods and Services Tax (CGST) Act, 2017, and State Goods and Services Tax (SGST) Act, 2017.

Nature of Alleged Violations

The GST demand order primarily alleges two main issues:

• Reverse Charge Mechanism: Alleged non-compliance with GST levy requirements under the reverse charge mechanism
• Input Tax Credit: Alleged excess availment of Input Tax Credit beyond permissible limits

The company has clearly stated that it does not agree with the allegations made in the demand order and intends to challenge the same through appropriate legal remedies.

Company's Response and Next Steps

Alkem Laboratories has indicated that it is in the process of taking appropriate action against the order, including filing an appeal with the relevant appellate authority. The company's response demonstrates its intention to contest the demand through established legal channels available under the GST framework.

Financial Impact Assessment

According to the company's disclosure, there is no material impact expected on the financial, operational, or other activities of the organization from this GST order. This assessment suggests that the company views the demand as contestable and expects to successfully challenge it through the appellate process.

The disclosure has been made available on the company's official website at www.alkemlabs.com , ensuring transparency and compliance with regulatory requirements for investor information.